Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Yuqin Song, Qingqing Cai, Ye Guo, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Yanyan Liu, Lanfang Li, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Lin-Chi Chen, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2025-3740

Published: 2025

Journal Articles

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Blood (2025) 146 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2025-1256

Published: 2025

Journal Articles

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He, Zhiming Li, Ningjing Lin, Ou Bai, Caixia Li, Xiaobo Wang, Yajun Li, Xingli Zhao, Huijing Wu, Xiaorui Fu, Zhihua Yao, Jiuyang Zhang, Ying Chen, Wei Meng, Zhuli Wu, Wenzhi Tian, Yuqin Song

Blood (2025) 146 (Supplement 1): 5358.

https://doi.org/10.1182/blood-2025-5358

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Yuqin Song, Ye Guo, Qingqing Cai, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Lanfang Li, Yanyan Liu, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Andrew Chow, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 5372.

https://doi.org/10.1182/blood-2025-5372

Published: 2025

Journal Articles

A parsimonious, clinically-interpretable logistic model for anemia in PLWHA: Feature selection with MCP penalization and validation in a retrospective cohort

Jingwen Zhang, Xiaoyan Lv, Junfeng Huo, Hui Shen, Pengpeng Li, yanyan Liu, guangzheng hu, Fuling Zhou

Blood (2025) 146 (Supplement 1): 7987.

https://doi.org/10.1182/blood-2025-7987

Published: 2025

Journal Articles

Erythroid PIM1 deficiency promotes hematopoietic aging via jun/jund activation and igkc-mediated proteostasis collapse

Yuping Guan, Yazhe Zhen, Taotao Li, Yanyan Liu, Zhihua Yao, Xinyang Zhao, Xiuli An, Shijie Zhang, Yuanlin Xu

Blood (2025) 146 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2025-4950

Published: 2025

Journal Articles

Machine learning models improve survival prediction in DLBCL: Analysis from the goya trial

Shuna Yao, Zian Lin, Bo Yang, Qingyao Shang, Binliang Liu, Meishuo Ouyang, Zhihua Yao, Yanyan Liu, Ken H. Young, Sheng Luo

Blood (2025) 146 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2025-3564

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Protein arginine methyltransferase 1 is required for megakaryocyte-mediated inflammatory response

Peipei Zhang, Anlun Li, Szumam Liu, Yanyan Liu, Hubert M. Tse, X. Long Zheng, Xinyang Zhao

Blood (2025) 146 (Supplement 1): 6579.

https://doi.org/10.1182/blood-2025-6579

Published: 2025

Journal Articles

Protein Arginine Methyltransferase 1 Expands and Mobilizes Immune Megakaryocytes and Generates Hyperactive Platelets in Stress Conditions

Peipei Zhang, Anlun Li, Yanyan Liu, X. Long Zheng, Xinyang Zhao

Blood (2024) 144 (Supplement 1): 1164.

https://doi.org/10.1182/blood-2024-208526

Published: 2024

Journal Articles

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lijuan Deng, Yanyan Liu, Ningjing Lin, Zhihua Yao, Jiuyang Zhang, Wei Meng, Qiying Lu, Wenzhi Tian, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2024-200539

Published: 2024

Journal Articles

A Novel Role of LKB1 in Erythroblast Enucleation

Yuanlin Xu, Jingxin Zhang, Yan Li, Huan Zhang, Peijun Jia, Yazhe Zhen, Wanxin Li, Tingting Zheng, Ying Zhang, Yihan Wang, Yilin Zhang, Yanyan Liu, Xiuli An, Shijie Zhang

Blood (2024) 144 (Supplement 1): 539.

https://doi.org/10.1182/blood-2024-209096

Published: 2024

Journal Articles

Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma

Shuang Zhao, Jiuyang Zhang, Zheng Yan, Yuanlin Xu, Zhihua Yao, Junfeng Chu, Shuna Yao, Haiying Wang, Wenping Zhou, Xufeng Luo, Peipei Zhang, Yanyan Liu

Blood (2023) 142 (Supplement 1): 6237.

https://doi.org/10.1182/blood-2023-185955

Published: 2023

Journal Articles

Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma

Shuna Yao, Zhihua Yao, Zheng Yan, Haiying Wang, Junfeng Chu, Shuang Zhao, Xinyang Zhao, Yanyan Liu

Blood (2023) 142 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2023-189345

Published: 2023

Journal Articles

Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up

Jianqiu Wu, Fei Li, Zhi-Jun Wuxiao, Weiyan Tang, Yue Teng, Yanyan Liu, Han Chu, Zhiya Wu, Yiwen Shen, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng

Blood (2023) 142 (Supplement 1): 6265.

https://doi.org/10.1182/blood-2023-181831

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study

Zheng Yan, Shuna Yao, Shuang Zhao, Haiying Wang, Junfeng Chu, Yuanlin Xu, Jiuyang Zhang, Lina Zhang, Quande Lin, Lijie Liang, Ping Wang, Wenyong Li, Xiaolu Teng, Zhihua Yao, Yanyan Liu

Blood (2023) 142 (Supplement 1): 3075.

https://doi.org/10.1182/blood-2023-185902

Published: 2023

Journal Articles

Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma

Zhihua Yao, Zheng Yan, Shuna Yao, Haiying Wang, Junfeng Chu, Shuang Zhao, Jie Ma, Bing Wei, Jiawen Zheng, Quande Lin, Zheng Xu, Xinyang Zhao, Yanyan Liu

Blood (2022) 140 (Supplement 1): 3767–3768.

https://doi.org/10.1182/blood-2022-165944

Published: 2022

Journal Articles

Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

Shuang Zhao, Yanyan Liu, Zhihua Yao, Zheng Yan, Shuna Yao, Junfeng Chu, Haiying Wang, Jiuyang Zhang, Peipei Zhang, Wenping Zhou

Blood (2022) 140 (Supplement 1): 6579–6580.

https://doi.org/10.1182/blood-2022-166829

Published: 2022

Journal Articles

A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Jianqiu Wu, Yanyan Liu, Li Fei, Zhi-Jun Wuxiao, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-142553

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

A parsimonious, clinically-interpretable logistic model for anemia in PLWHA: Feature selection with MCP penalization and validation in a retrospective cohort

Erythroid PIM1 deficiency promotes hematopoietic aging via jun/jund activation and igkc-mediated proteostasis collapse

Machine learning models improve survival prediction in DLBCL: Analysis from the goya trial

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Protein arginine methyltransferase 1 is required for megakaryocyte-mediated inflammatory response

Protein Arginine Methyltransferase 1 Expands and Mobilizes Immune Megakaryocytes and Generates Hyperactive Platelets in Stress Conditions

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

A Novel Role of LKB1 in Erythroblast Enucleation

Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma

Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma

Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study

Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma

Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only